pathios therapeutics
Pathios Therapeutics is a clinical-stage biotech company developing small-molecule inhibitors that target the acid-sensing GPCR, GPR65, to treat solid tumors. The company's lead asset, PTT-4256, is an orally-bioavailable selective inhibitor designed to reverse immune cell dysfunction caused by the acidic tumor microenvironment. Their approach focuses on modulating the activity of T cells, natural killer cells, and macrophages to restore anti-cancer immune responses.
Biotechnology
Oncology
Immunology
Pharmaceuticals
Funding summary
- Total raised
- €7.6M
- Funding rounds
- 1
Investors in pathios therapeutics
Investors on record for pathios therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like pathios therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors